Subscribe To
DGNOF / DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023
BROSSARD, Quebec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) is a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI). DIAGNOS and École de Technologie Supérieure (ÉTS), a world-renowned technical university, are proud to announce that they will be presenting the results of their ground-breaking research on mass screening for macular edema using Optical Coherence Tomography (OCT) at ARVO 2023, the Annual Conference of the Association for Research in Vision and Ophthalmology (ARVO).
Read More
Posted: Feb 14 2023, 10:37
Author Name: GlobeNewsWire
Views: 102726
DGNOF News
By GlobeNewsWire
February 14, 2023
DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023
BROSSARD, Quebec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) more_horizontal